Document Type : Original Article

Authors

1 Surgical Oncology Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran

2 Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Biomedical and Clinical Sciences (BKV), Linköping University, Linköping, Sweden

4 Department of Pathology, Qaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: Papillary thyroid carcinoma (PTC) is the most prevalent malignancy of the endocrine system. This study was aimed at evaluating the serum substance P (SP) levels, the tissue distribution of Neurokinin-1 receptors (NK1-R), and their possible diagnostic value in PTC.
Method: The present case-control study included 31 healthy volunteers and 31 cases (age range: 25-64, 40.26 ±12.77) who were primarily diagnosed with PTC and were candidates for total thyroidectomy. Pre-operative serum level of SP was measured using a commercial ELISA kit. The tissue distribution of NK1-R was assessed immunohistochemically.
Results: The serum level of SP in the patient group was higher than the healthy volunteers (P-value =.005). Besides, the expression of NK1-R was higher in tumoral tissues compared with their normal surroundings (P-value =.005). However, we observed no significant correlation between either SP level or NK1-R expression and the disease stage or lymph node involvement.
Conclusion: SP level and NK1-R expression were upregulated in PTC patients, showing the involvement of SP/NK1R complex in PTC pathophysiology. Nonetheless, proposing SP/NK1R as a diagnostic factor requires further studies because we found no correlation between SP/NK1R and clinical stage or lymph node involvement.

Keywords

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination, and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.30476/mejc.2020.85658.1297